X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The I-SPY COVID Trial was halted by Quantum Leap Healthcare Collaborative because Aerpio's razuprotafib was difficult to administer in the setting of COVID-19, with 30% of patients discontinuing the agent due to disease-related hypotension.
Lead Product(s): Razuprotafib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AKB-9778
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Quantum Leap Healthcare
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2021
Details:
Razuprotafib a first-in-class small molecule inhibitor of vascular endothelial protein tyrosine phosphatase, is being developed as a treatment for open angle glaucoma, and the Company intends to investigate the therapeutic potential of razuprotafib in other indications.
Lead Product(s): Razuprotafib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AKB-9778
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
The study is designed to evaluate the safety and efficacy of a topical ocular formulation of razuprotafib in approximately 195 patients followed over a 28-day period, and patients must undergo a 28-day washout prior to randomization.
Lead Product(s): Razuprotafib
Therapeutic Area: Ophthalmology Product Name: AKB-9778
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2020
Details:
First patient with razuprotafib in the I-SPY COVID Trial, a phase 2 platform trial aimed at improving treatment of acute respiratory distress syndrome (ARDS) in severely ill COVID-19 (adult) patients.
Lead Product(s): Razuprotafib,Remdesivir
Therapeutic Area: Infections and Infectious Diseases Product Name: AKB-9778
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Quantum Leap Healthcare
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2020
Details:
Aerpio is developing a selective small molecule inhibitor of vascular endothelial protein tyrosine phosphatase, razuprotafib (AKB-9778), that restores Tie2 pathway activation in endothelial cells to stabilize blood vessels during vascular injury and inflammation.
Lead Product(s): Razuprotafib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AKB-9778
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: MTEC
Deal Size: $5.1 million Upfront Cash: Undisclosed
Deal Type: Funding August 04, 2020
Details:
Aerpio Pharmaceuticals has commenced patient enrollment in its double-blind, placebo-controlled Phase 2 trial in patients with elevated intraocular pressure (IOP) associated with open angle glaucoma (OAG) or ocular hypertension (OHT).
Lead Product(s): Razuprotafib
Therapeutic Area: Ophthalmology Product Name: AKB-9778
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2020
Details:
The collaboration aims at evaluating razuprotafib in a new randomized, investigational treatment arm in the I-SPY COVID Trial for the treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19.
Lead Product(s): Razuprotafib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Quantum Leap Healthcare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 27, 2020
Details:
The Phase 1b trial is a randomized, double-masked study designed to assess increasing concentrations of AKB-9778 dosed topically as eye drops.
Lead Product(s): Razuprotafib,Prostaglandin
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2020
Details:
Topical ocular administration of AKB-9778 was well tolerated over seven days in cohort 5.
Lead Product(s): Razuprotafib,Prostaglandin
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
